SCHEMBL29334145

SCHEMBL29334145

CC(C)(C)OC(=O)N1CCOC[C@H]1c1cc(Cl)cc(C#N)c1

nearest known ligand 0.39

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
▸ GRM5 P41594 2/20 0.39
▸ MALT1 Q9UDY8 1/20 0.38
▸ GPR119 Q8TDV5 6/20 0.36
▸ AR P10275 1/20 0.35
▸ USP2 O75604 1/20 0.35
▸ SMN1; SMN2 Q16637 1/20 0.35
▸ CCNC P24863 1/20 0.35
▸ CDK8 P49336 1/20 0.35
▸ NR1H2 P55055 1/20 0.35
▸ NR1H3 Q13133 1/20 0.35
▸ MEN1 O00255 1/20 0.35
▸ LMNA P02545 1/20 0.35
▸ MAPT P10636 1/20 0.35
▸ TSHR P16473 1/20 0.35
▸ HTT P42858 1/20 0.35
▸ KMT2A Q03164 1/20 0.35
▸ NPSR1 Q6W5P4 1/20 0.35
▸ STS P08842 2/20 0.34
▸ OPRK1 P41145 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29333856 0.84 MALT1 (0.39) GRM5MALT1USP2SMN1; SMN2CCNC
SCHEMBL29333833 0.84 MALT1 (0.39) GRM5MALT1USP2SMN1; SMN2CCNC
SCHEMBL30855098 0.84 MALT1 (0.39) GRM5MALT1USP2SMN1; SMN2CCNC
SCHEMBL29333998 0.84 MALT1 (0.39) GRM5MALT1USP2SMN1; SMN2CCNC
SCHEMBL29333947 0.83 MALT1 (0.36) GRM5MALT1USP2SMN1; SMN2CCNC
SCHEMBL29333842 0.83 USP2 (0.39) GRM5MALT1USP2SMN1; SMN2CCNC
SCHEMBL29333969 0.82 MALT1 (0.38) GRM5MALT1USP2SMN1; SMN2CCNC
SCHEMBL29334004 0.81 MALT1 (0.38) GRM5MALT1USP2SMN1; SMN2CCNC
SCHEMBL29333893 0.81 MALT1 (0.40) MALT1USP2SMN1; SMN2CCNCCDK8
SCHEMBL31224883 0.80 MALT1 (0.44) GRM5MALT1USP2SMN1; SMN2CCNC

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4594308-A1 N-ACRYLOYLMORPHOLINE DERIVATIVES AS KEAP1 MODULATORS AND USES THEREOF Vividion Therapeutics, Inc. (US) 2025-08-06 — — EP disclosed
US-20240226114-A1 INHIBITORS AND USES THEREOF VIVIDION THERAPEUTICS, INC. 2024-07-11 — — US disclosed
US-20240226114-A1 INHIBITORS AND USES THEREOF VIVIDION THERAPEUTICS, INC. 2024-07-11 — — US disclosed
US-20240226114-A1 INHIBITORS AND USES THEREOF VIVIDION THERAPEUTICS, INC. 2024-07-11 — — US disclosed
WO-2024073587-A1 N-ACRYLOYLMORPHOLINE DERIVATIVES AS KEAP1 MODULATORS AND USES THEREOF VIVIDION THERAPEUTICS, INC. (US) 2024-04-04 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240226114-A1 INHIBITORS AND USES THEREOF KEAP1, NQO1, NFE2L2 GRM5 3661/4885MALT1 4516/4885GPR119 2964/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback